This emedtv segment explains how glucophage works and includes detailed information on its benefits, dosages, and potential side effects and glucotrol. Glucose by ADA glucose of 110-125 ; was present in only 48% of individuals classified as having impaired glucose tolerance by WHO 140-199 ; . The ADA criteria were much less sensitive than the WHO criteria in predicting CVD mortality sensitivity 28% vs 54% ; . The groups seem to differ phenotypically, with the impaired fasting glucose by ADA 110-125 ; more likely in the middle aged and obese. Impaired fasting glucose by ADA 110-129 ; is not as sensitive as impaired glucose tolerance by WHO 140-199 ; in measuring lesser degrees of glucose intolerance. "For people who advocate a switch towards the exclusive use of fasting glucose concentrations to define glucose tolerance, the findings of the DECODE study make worrying reading." Macrovascular disease cardiovascular disease ; accounts for most of the excess mortality associated with type 2 diabetes. The relation between hyperglycemia and mortality from cardiovascular disease is complex. Glucose intolerance, defined as fasting or postprandial concentrations at the upper end of the normal distribution in population based studies is accompanied by increased prevalence of, and mortality from, cardiovascular disease. Postprandial, rather than fasting glucose, is a better prognostic indicator. In the DECODE study, people with a normal fasting glucose 110 ; formed the group with the largest number of excess deaths. This group makes up a third of all men and half of all women with any degree of glucose intolerance. It should not be ignored. Lancet August 21, 1999; 354: Editorial by Melanie Davies, Leicester Royal Infirmary, Leicester, UK Comment: Many individuals with a normal fasting glucose level do indeed have glucose intolerance. I suspect that those with lower fasting levels eg, 90 ; will be less likely to have glucose intolerance than those with fasting levels 105-110. We should be aware of the possible risks in patients with high normal levels. 8-8 EFFECTS OF METFORMIN IN PATIENTS WITH POORLY CONTROLLED INSULIN-TREATED TYPE 2 DIABETES. Because many persons with type 2 diabetes are overweight and insulin resistant, high doses of insulin are often required to achieve adequate glycemic control. Insulin is associated with weight gain which attenuates the expected improvement in glycemic control. It is now common to combine therapeutic agents that have complementary mechanisms of action for therapy of type 2 diabetes. Metformin [Glucophage ] , a biguanide, is approved for use alone or in combination with sulfonylureas. Its main mechanisms of action are: 1 ; to decrease hepatic glucose output, and 2 ; to improve peripheral insulin sensitivity. Some authorities recommend metformin as the drug of first choice in patients with type 2 diabetes who are obese. Combining metformin with insulin may improve glycemic control and insulin sensitivity while avoiding weight gain. This study evaluated the efficacy of combined metformin insulin in patients with type 2 diabetes who were poorly controlled by insulin alone. Conclusion: The combination lowered HbA1c levels and reduced insulin requirements. STUDY.

PSNC produces NHS guide A guide to the NHS in England and Wales has been produced for community pharmacists by the Pharmaceutical Services Negotiating Committee. It aims to help contractors understand the structure and role of NHS organisations. BNF and Pharmaid Pharmacists are reminded not to throw away copies of BNF 46 now that the 47th edition has been published. Outdated copies can be retained until the annual Pharmaid collection later this year or can be sent to Betty Falconbridge, Administrator, Commonwealth Pharmaceutical Association, 1 Lambeth High Street, London SE1 7JN. Minimum wage to rise National minimum wages will rise from 1 October. For adults, the rate rises from 4.40 to 4.85 an hour, while the minimum pay for 1821 year-olds rises from 3.80 to 4.10 an hour and a new minimum rate for 16 and 17 year-olds of 3 an hour is introduced and glyburide, for example, glucophage and alcohol.
Gsjjs1 , the glucophage worked for me within 3 weeks of my first pill. Can make more nexium people pepcid pneumonia prilosec, lawsuit paxil, alprazolam fedex, anxiety paxil, diflucan, amoxicillin, alprazolam, zyban, ativan, paxil, fluoxetine, nexium, klonopin, glucophage alprazolam tafil, opinion paxil professional withdrawal and hydrochlorothiazide. These drugs reduce the amount of glucose that is made by the liver and helps the body better use insulin. Generic name Brand name metformin Glucophsge metformin Gucophage XR Nausea, diarrhea, gas, loss of appetite. Oral med category target area in the body how it works common brand names common side effects sulfonylureas pancreas causes the pancreas to release more insulin amaryl, diabeta, diabinese, glucotrol, glyburide, glynase, micronase, tolinase, orinase hypoglycemia, weight gain use with caution with liver or kidney disease meglitinides pancreas very similar to sulfonylureas, but is fast in, fast out prandin, starlix hypoglycemia, although less often than with sulfonylureas, and weight gain biguanides liver keeps the liver from releasing too much glucose glucophage, also called metformin nausea, diarrhea; avoid with kidney disease or excess alcohol intake alpha-glucosidase inhibitors small intestine slows digestion of some carbohydrates, which lowers the post-meal glucose precose, glyset flatulence gas ; , diarrhea; avoid with bowel disease; special instructions to treat hypoglycemia thiazolidinediones called tzds ; muscle cells receptors targets insulin resistance: makes muscle cells more sensitive to insulin actos, avandia weight gain, edema; monitor liver function; caution with heart problems conclusions: important note: i only listed the main points about each drug and hydrocodone. Assess the client's medical, preventative and psychological support services and how their needs are met by these existing services. Take all suicidal thoughts or ideas seriously. Work to provide support for the individual immediately. Use the Service Provider Resource Referral Template Appendix B ; to assist the client in receiving immediate counselling. If necessary, call for ambulance assistance. Refer to the ethical codes or guidelines of your organization or professional body for more information on addressing suicidal ideations. Help the client make plans for the future. This will include reminding them of the plans they made in the pre-test session. Talk through the plan with them. Help the client establish a plan for continuing medical, social and psychological support. This may include setting up future appointments with the client or referring them to an appropriate agency. Discuss any signs or symptoms of the infection. Explain the consequences of having an HIV infection and how it can be treated. Explore any recent behaviour that may have put others at risk or that may have put them at risk for an additional STI. Make sure the client understands the consequences of the infection for both themselves and their sexual partners. Discuss what it means to be in sero-discordant relationship see glossary on page 16 for details ; . Offer an opportunity to repeat the test. Work with the client to create a harm-reduction plan. Harm-reduction plans assist in helping clients make decisions about how they will approach sexual activities or drug use in the future. Developing a harm-reduction plan should be done for clients as a way of reducing risk of STI HIV re-infection for themselves and infection for the people with whom they are intimately involved. Adderall Amphetamine with Dextroamphetamine Salt Combination ; Aldactone Spironolactone ; Amaryl Glimepiride ; Anaprox Naproxen ; Arava QL Leflunomide QL ; Ativan Lorazepam ; Augmentin, Augmentin ES Amoxicillin with Potassium Clavulanate ; Buspar Buspirone ; Calan, Calan SR Verapamil ; Capoten Captopril ; Cardizem CD except for 360mg strength Diltiazem Sustained Release 24 Hour Capsule ; Cardura Doxazosin ; Ceftin Cefuroxime ; Celexa QL Citalopram QL ; Ciloxan Eye Drops Ciprofloxacin ; Cipro Ciprofloxacin ; Cleocin T Clindamycin Gel, Lotion, Solution, Swabs ; Copegus QL, N RibavirinQL, N ; Darvocet-N Propoxyphene with Acetaminophen ; DDAVP Desmopressin ; Dexedrine SR Dextroamphetamine Sustained Release Capsule ; DiaBeta, Micronase, Glynase Glyburide ; Didronel Etidronate Disodium ; Diflucan 50, 100, 200mg Tablet N Fluconazole N ; Diflucan 150mg QL Fluconazole QL ; Diprolene AF Betamethasone Dipropionate Augmented Cream ; Duricef Cefadroxil ; Dyazide Triamterene with Hydrochlorothiazide ; Dynacirc Isradipine ; Elocon Cream, Ointment Mometasone ; Eskalith CR Lithium Carbonate Controlled-Release ; Fioricet Butalbital with Acetaminophen and Caffeine ; Flexeril Cyclobenzaprine ; Glucophage, XR Metformin ; Glucotrol, XL Glipizide ; Hytrin Terazosin ; Inderal Propranolol ; Keflex Cephalexin ; Klonopin Clonazepam ; Lasix Furosemide ; Lithobid Lithium Carbonate Extended-Release ; Lopid Gemfibrozil ; Lopressor Metoprolol ; Lotensin Benazepril ; Lotensin HCT Benazepril with Hydrochlorothiazide ; Lotrisone Betamethasone with Clotrimazole ; Macrobid Nitrofurantoin Nitrofurantoin Macrocrystal ; Medrol Dosepak Methylprednisolone ; Metrocream Metronidazole Cream ; Mevacor QL QD Lovastatin QL QD ; Motrin Ibuprofen ; - Prescription strengths only Mycelex Troche Clotrimazole Troche ; Naprosyn Naproxen ; - Prescription strengths only Neurontin Capsule, Tablet Gabapentin ; Nizoral Ketoconozole ; Ocuflox Eye Drops Ofloxacin ; Percocet 5-325, 7.5-500, 10-650 Oxycodone with Acetaminophen ; Plendil Felodipine ; Pletal Cilostazol ; Prinivil, Zestril Lisinopril ; Prinzide, Zestoretic Lisinopril with Hydrochlorothiazide ; Procardia XL Nifedipine Extended-Release ; Proventil Inhaler QL, Ventolin Inhaler QL Albuterol Inhaler QL ; Provera Medroxyprogesterone ; Prozac QL Fluoxetine QL ; Rebetol QL, N Ribavirin QL, N ; Remeron QL Mirtazapine QL ; Remeron SolTab QL Mirtazapine Dispersible Tablet QL ; Restoril 15, 30mg Temazepam ; Ritalin Methylphenidate ; Ritalin SR Methylphenidate Extended-Release ; Sporanox QL, N Itraconazole QL, N ; Tenormin Atenolol ; Tenoretic Atenolol with Chlorthalidone ; Terazol 3 Cream Terconazole ; Tylenol #3 Acetaminophen with Codeine ; Ultracet QL Tramadol with Acetaminophen QL ; Ultram QL Tramadol QL ; Ultravate Cream, Ointment Halobetasol Propionate ; Valium Diazepam ; Vaseretic Enalapril with Hydrochlorothiazide ; Vasotec Enalapril ; Vicodin Acetaminophen with Hydrocodone ; Vicoprofen Ibuprofen with Hydrocodone ; Videx EC 200, 250, 400mg Didanosine Capsule Delayed Release ; Voltaren Tablet Diclofenac ; Wellbutrin QL Bupropion QL ; Wellbutrin SR QL, N Bupropion Sustained Release QL, N ; Xanax, Xanax XR Alprazolam ; Ziac Bisoprolol with Hydrochlorothiazide ; Zonegran Zonisamide ; Zovirax Tablet, Capsule, Suspension Acyclovir and hyzaar.

Glucophage oral Glucophage and glucophage xr are used to treat type 2 diabetes. Benijts, T., Dams, R., Lambert, W. and De Leenheer, A. 2004a ; . Countering matrix effects in environmental liquid chromatography- electrospray ionization tandem mass spectrometry water analysis for endocrine disrupting chemicals. J Chromatogr A, 1029: 153-159. Benijts, T., Gunther, W., Lambert, W. and DeLeenheer, A. 2003 ; . Sonic spray ionization applied to liquid chromatography mass spectrometry analysis of endocrine-disrupting chemicals in environmental water samples. Rapid Commun. Mass Spectrom., 17: 1866-1872. Benijts, T., Lambert, W. and DeLeenheer, A. 2004b ; . Analysis of multiple endocrine disruptors in environmental waters via wide-spectrum solid-phase extraction and dualpolarity ionization LC- ion trap-MS MS. Anal. Chem., 76: 704-711. Benito-Pena, E., Partal-Rodera, A. I., Leon-Gonzalez, M. E. and Moreno-Bondi, M. C. 2006 ; . Evaluation of mixed mode solid phase extraction cartridges for the preconcentration of beta-lactam antibiotics in wastewater using liquid chromatography with UV-DAD detection. Anal. Chim. Acta, 556: 415-422. Bennie, D. T. 1999 ; . Review of the environmental occurrence of alkylphenols and alkylphenol ethoxylates. Water Qual. Res. J. Canada, 34: 79-122. Berset, J. D. and Etter-Holzer, R. 2001 ; . Determination of phthalates in crude extracts of sewage sludges by high-resolution capillary gas chromatography with mass spectrometric detection. J. AOAC. Int, 84: 383-391. Berset, J. D., Bigler, P. and Herren, D. 2000 ; . Analysis of nitro musk compounds and their amino metabolites in liquid sewage sludges using NMR and mass spectrometry. Anal. Chem., 72: 2124-2131. Berset, J. D., Kupper, T., Etter, R. and Tarradellas, J. 2004 ; . Considerations about the enantioselective transformation of polycyclic musks in wastewater, treated wastewater and sewage sludge and analysis of their fate in a sequencing batch reactor. Chemosphere, 57: 987-996. Bester, K. 2003 ; . Triclosan in a sewage treatment process - balances and monitoring data. Water Res., 37: 3891-3896. Bester, K. 2004 ; . Retention characteristics and balance assessment for two polycyclic musk fragrances HHCB and AHTN ; in a typical German sewage treatment plant. Chemosphere, 57: 863-870. Bester, K., Theobald, N. and Schroder, H. F. 2001 ; . Nonylphenols, nonylphenol-ethoxylates, linear alkylbenzenesulfonates LAS ; and bis 4-chlorophenyl ; -sulfone in the German Bight of the North Sea. Chemosphere, 45: 817-826. Biles, J. E., McNeal, T. P., Begley, T. H. and Hollifield, H. C. 1997 ; . Determination of bisphenol A in reusable polycarbonate food-contact plastics and migration to foodstimulating liquids. J. Agr. Food Chem., 45: 3541-3544 and ibuprofen. Compared to placebo p 0.056 ; . There was no statistically significant difference in any of these parameters between male and female diabetic subjects, nor between diabetic subjects treated with thiazolidinediones and those not treated with these drugs, for example, glucohage and alcohol.

Cheap Glucophage Paxil-prescriptions online pharmacy source please select weight loss muscle relaxants men's health women's health sexual health pain relief migraine relief enhancement antifungal quit smoking anti depressants anxiety skin care laxatives allergy relief heartburn relief sleeping aids weight loss adipex bontril didrex ionamin meridia phentermine tenuate xenical phendimetrazine slimpro fattache dermalin-apg dermaloss weight loss weight loss compound le patch unidiyne free ephedra ansi hydroxadrine nutrasport eca stack syntrax guggubolic hydroxycut muscle relaxants cyclobenzaprine skelaxin soma flexeril zanaflex men's health propecia viagra levitra accupril actonel actos aldactone spironolactone allopurinol altace symmetrel amantadine amaryl amoxicillin amoxil anusol atenolol avandia avapro biaxin captopril cartia xt cefzil cephalexin evoxac cevimeline cipro clonidine coreg cozaar detrol la bentyl dicyclomine diltiazem hci diovan ditropan xl doxazosin enalapril maleate flomax flumadine rimantadine fosamax furosemide gemfibrozil glipizide glucophags xr isosorbide mononitrate levaquin lipitor lisinopril lotensin vermox mebendazole metformin hci metoprolol tartrate microzide minocycline monopril norvasc oretic oseltamivir penicillin v plavix pravachol prevacid prinivil prochlorperazine proctocort hydrocortizone proctocream propranolol protonix spironolactone sumycin tetracycline terazosin tetracycline tiazac toprol-xl trimox zanamivir zestoretic zestril zithromax zyloprim allopurinol women's health ortho tri-cyclen vaniqa nordette 28 menopro ortho evra patch triphasil diflucan estradiol ovral accupril actonel actos aldactone spironolactone alesse allopurinol altace symmetrel amantadine amaryl amoxicillin amoxil anusol atenolol avandia avapro biaxin captopril cartia xt cefzil cephalexin evoxac cevimeline cipro clonidine coreg cozaar detrol la bentyl dicyclomine diltiazem hci diovan ditropan xl doxazosin enalapril maleate flumadine rimantadine fosamax furosemide gemfibrozil glipizide glucophzge xr isosorbide mononitrate levaquin lipitor lisinopril lotensin vermox mebendazole metformin hci metoprolol tartrate microzide minocycline mircette monopril norvasc oretic oseltamivir penicillin v plavix pravachol prevacid prinivil prochlorperazine proctocort hydrocortizone proctocream propranolol protonix spironolactone sumycin tetracycline terazosin tetracycline tiazac toprol-xl trimox zanamivir zestoretic zestril zithromax zyloprim allopurinol sexual health acyclovir valtrex viagra levitra zovirax pain relief celebrex ultram vioxx tramadol bluepro flextra-ds aphthasol amlexanox bextra colchicine diclofenac motrin ibuprofen naprosyn naproxen naproxen nifedipine migraine relief imitrex fioricet depakote enhancement bustpro v-pro formula hgh hgh15 mindpro ergopharm 1-ad moodpro ast multi-pro 32x anti fungal lamisil griseofulvin ketoconazole terbinafine quit smoking zyban anti-depressants paxil prozac zoloft effexor elavil fluoxetine wellbutrin sarafem celexa amitriptyline nortriptyline remeron seroquel trazodone zyprexa anxiety buspar clonazepam skin care retin a renova genie smoother acne series - kit advanced tantowel body replenishing lotion clarifying tonic daily defense moisturizer dermaclear acne gel dermashield sunscreen dermaworld - kit evolution exfoliating body wash facial cleanser hydration therapy anti-aging serum rosacea gel seasonal kit strivectin-sd sunlesstanner x-foliator x-tend collagen cream betamethasone dovonex calcipotriene fluocinolone ultravate halobetasol hydroquinone selsun selenium sulfide protopic tacrolimus kenalog triamcinolone laxatives senokot-s lactulose allergy relief allegra claritin flonase nasacort nasonex zyrtec antivert meclizine atarax hydroxyzine meclizine promethazine scopolamine heartburn relief prilosec aciphex nexium sleeping aids ambien sonata antifungal onychomycosis is a fungal infection of fingernails or toenails and imitrex. Levels of Skill Use It is perhaps not surprising to note that the level of positive skill use was greater in the episodes rated effective Table 2 ; than in those classed as ineffective Table 3 ; by a margin of over 2: 1 average 7.9 skills to 3.5 skills episode ; . This observation adds weight to the internal consistency and validity of the results in that there would appear to be a direct relationship between communication effectiveness and frequency of skill use. It must, however, be borne in mind that in several instances where the frequency of skill use was relatively high i.e. 6 or 7 ; , the episode was rated ineffective Table 3 ; , whereas up to this level of use was deemed effective in 8 episodes, and indeed in one effective consultation only two skills were identified. Thus, while generally a higher proportion of skill use occurs in effective consultations, such consultations can also be the product of less frequent, but judicious, application of communication skill. Equally, merely the more frequent use of a behaviour does not necessarily guarantee successful communication Arkowitz, 1981 ; . When the profile of skills was examined in terms of the frequency of individual skill use in both effective and ineffective episodes Table 4 ; , a number of other factors emerged. In only one skill, that of questioning, was there an increased level of use in the ineffectively rated interactions. Where listening was concerned there was an 11-fold increase in the effective as opposed to ineffective consultations, suggesting that the ability to overtly listen is a key factor to effectiveness in community pharmacy. Similarly rapport building showed a fourfold increase, and the link between these two behaviours may be inferred. For example, the sub-categories under rapport building such as availability, showing interest and concern, helpfulness, referring to patients by name and recalling family circumstances are all indicative of listening behaviour. In considering the nature of the episodes chosen as effective or ineffective, Table 3 indicates a higher preponderance of request type interactions and a total of six interactions where antibiotics were involved. The majority of these antibiotic situations involved a request for a medication which was not available without a doctor's prescription. Thus, while pharmacists 82. This medicine 5% cream 2g pump x 3 and isosorbide. Glucophage medicine

Your doctor should have been able to determine if you have one of the conditions that requires you to stop glucophage.

Antidiabetics saw an increase in overall drug trend from 14.6% in 2002 to 23.1% in 2003. Costs per prescription and utilization growth, particularly an increase in prevalence, contributed about equally to the overall increase. The prevalence of Type 2 diabetes has reached nearly epidemic magnitude in the United States, with more new patients taking oral agents and insulin. Costs due to brand generic mix returned to near-normal levels in 2003, after dropping significantly in 2002 due to the Glucophagge patent expiration. Inflation rose as well, with many of the newer insulin products showing the largest gains. Metformin continued to be the market-share leader. Other oral drugs, Actos and Avandia, showed mixed results. Actos grew in market share to 9.2%, but Avandia share decreased by 0.1% to 8.2%. If the newer product AvandametTM a combination of metformin and Avandia ; , which had a 1% share in 2003, is included, the Avandia family of products also had a 9.2% share in 2003. These products continued to outpace the rest of the oral antidiabetic class in terms of average cost per prescription, with Actos at 2.2 times the average cost of the class, and Avandia at 1.8 times the class average and lanoxin.
Aldactone spironolactone Axid nizatidine Betapace sotalol Birth Control TBD Buspar buspirone Cardizem diltiazem Claritin loratadine Cylert pemoline Ditropan oxybutynin Eldepryl selegiline Glucpohage metformin K DUR potassium chloride, Slow K, Klor-Con M Klonopin clonazepam Mycelex clotrimazole Prilosec omeprazole Prinivil lisinopril Procardia nifedipine Pronestyl procainamide Prozac Sarafem ; fluoxetine Remeron mirtazapine Ritalin & long acting ; methylphenidate, Metadate, Methylin Soma carisoprodol Tranxene clorazepate Ultram tramadol Vasotec enalapril Wellbutrin bupropion Zestril lisinopril Note: This is an example of the table. More drugs will be included. This table is for statewide public reporting. The information can be reported by geographic area. If participating health plans are interested, the Office of Health Care Statistics can produce internal reports for each plan.
Returned to normal in lung tissue Fig. 1 ; . In addition to these tissues, we examined the SSAO activity in pancreas and small intestine, but neither of these two tissues showed any altered activity as a result of the alloxan treatment data not shown ; . Linear regression suggests that the SSAO activity in serum is positively correlated with blood glucose levels p 0.0499 ; 7 days after the induction of diabetes Fig. 2 ; . We performed linear regression on data from the alloxan-treated animals only. SSAO mRNA was quantified in two sets of cDNA prepared twice from the same RNA ; by realtime PCR. These analyses showed that the mRNA levels were approximately 140 times higher in adipose compared to lung tissue Table 2 ; . We also found that the mRNA levels were lower in adipose tissue from diabetic animals compared to controls as early as 1 day after the alloxan injection p 0.0101 and 0.0017, for cDNA set 1 and 2, respectively.

Glucophage notes do not share glucophage with others.

Requirements. The studies were controlled, each one with at least 6 exposures, they were in english, and period of exposure first trimester ; as well as the type of congenital anomalies were clearly recorded. It has been possible to examine specific defects, but the dosage and the reason for aspirin intake could not be scrutinized. Here are the main results: - OR for any type of congenital anomalies in exposures during the 1st trimester, relevant to 8 studies for various defects 1.3 CI 95%: 0.9-1.9 ; . The 8 studies mentioned above were divided as follows: 5 cohort studies Turner and Collins 1975, Slone et al 1976, Newman et al 1977, Aselton et al 1985, Siffel and Czeizel 1955 ; , 2 case-control studies Nelson and Forfar 1971, Richards 1972 ; and 1 randomized study Pattison et al 2000 ; . When the analysis was done considering the different type of study a risk increase was hyghlighted in the case-control group: OR 1.6 CI 95%: 1.3-2.0 ; , whereas no increase was noticed in cohort studies or in the controlled randomized study: OR 1.0 CI 95%: 0.9-1.1 ; . Unfortunately there was no uniformity of results within each group, and this was probably due to the presence of recall bias in the case-control studies, where healthy newborns were chosen as controls. - OR for CNS defects, in newborns exposed during the first trimester 1 cohort study: Slone et al 1976 and 3 case-control study: Richards 1972, Winship et al 1984, KarkinenJaaskelainen anad Saxen 1974 ; 1.4 CI 95%: 0.9-2.2 ; . The analysis of the case-control studies shows a rinsk increase: OR 1.7 CI 95%: 1.2-2.3 ; , to be partially attributed to a memory bias often occurring in such studies. - OR for DTN defects, in newborns exposed during the first trimester 3 case-control studies: Richards 1972, Lynberg et al 1994, Shaw et al 1998 ; 2.2 CI 95%: 0.9-5.2 ; . - OR for congenital cardiopathies in newborns exposed during the first trimester 1.0 CI 95%: 0.9-1.1 ; reported as follows: 2 cohort studies Turner and Collins 1975, and Slone et al 1976 ; 4 case-control studies Richards 1972, Zierler and Rothman 1985, Werler et al 1989, and Tikkanen and Heinonen 1992 ; . - OR for gastroschisis, in newborns exposed during the first trimester as in 5 case-control studies Gierup and Lundkvist 1979, Drongowski et al 1991, Werler et al 1992, Torfs et al 1996, Martinez-Frias et al 1997 ; 2.4 CI 95%: 1.4-3.9 ; . - OR for gastrointestinal defects, in newborns exposed during the first trimester as in 1 cohort study Slone et al 1976 ; and 1 case-control study Richards 1972 ; 1.0 CI 95%: 0.6-1.5 ; . They were heterogeneous studies. - OR for oral clefts, in newborns exposed during the first trimester as in 2 case-control studies Richards 1972 and Saxen 1975 ; 2.9 CI 95%: 2.0-4.0 ; . - OR for skeletal muscle defects, in newborns exposed during the first trimester as in 1 cohort study Slone et al 1976 ; and 1 case-control study Richards 1972 ; 0.9 IC 95%: 0.8-1.1 ; . - OR for hypospadia, in newborns exposed in the first trimester as in 2 cohort studies Correy et al 1991 and Slone et al 1976 ; 1.8 CI 95%: 0.6-5.7 ; . - OR for pylorus stenosis, in newborns exposed during the first trimester as in 1 case-control study Richards 1972 ; 2.2 IC 95%: 1.0-5.0 ; . Retrospective cohort studies with internal controls Rosa 1993 ; , Michigan MSS: of 1, 709 first trimester exposures, 83 newborns with major defects, 73 expected: RR 1.1 CI 95%: 0.9-1.4 ; . Case-control studies, specific Abe et al 2003 ; : of 192 newborns with renal defects, 6 had been exposed in the first trimester. Of 3, 029 healthy controls proportionally matched as per year and birth hospital, 29 had been exposed. AOR 3.5 CI 95%: 1.4 8.8 ; , no difference between renal and obstructive anomalies. The exposure concerned intake of over-the counter drugs and it is possible that the survey was influenced by a memory or interview bias. Medveczky et al 2004 ; , Hungarian CCSCA: of 1, 202 newborns with DNT, 13 were exposed during the second month of gestation critical period for DNT ; . Of 38, 151 healthy controls, 173 were exposed with OR 2.0 CI 95%: 1.2-3.6 ; and of 22, 475 controls with all the other congenital defects, 148 exposed with OR 1.5 CI 95%: 0.82.6 ; . The result, authors suggest, should be to to memory bias, for example, glucophage information.